Literature DB >> 21320292

In vitro studies of dasatinib, its targets and predictors of sensitivity.

Lucia B Jilaveanu, Christopher R Zito, Saadia A Aziz, Ashok Chakraborty, Michael A Davies, Robert L Camp, David L Rimm, Arkadiusz Dudek, Mario Sznol, Harriet M Kluger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21320292      PMCID： PMC4431976          DOI： 10.1111/j.1755-148X.2011.00835.x

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN： 1755-1471            Impact factor:   4.693


× No keyword cloud information.
  11 in total

1.  Activation of phosphatidylinositol 3-kinase by a complex of p59fyn and the receptor tyrosine kinase Xmrk is involved in malignant transformation of pigment cells.

Authors:  C Wellbrock; M Schartl
Journal:  Eur J Biochem       Date:  2000-06

2.  Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection.

Authors:  Fei Huang; Karen Reeves; Xia Han; Craig Fairchild; Suso Platero; Tai W Wong; Francis Lee; Peter Shaw; Edwin Clark
Journal:  Cancer Res       Date:  2007-03-01       Impact factor: 12.701

3.  A phase 2 trial of dasatinib in advanced melanoma.

Authors:  Harriet M Kluger; Arkadiuz Z Dudek; Carrie McCann; Jean Ritacco; Nadine Southard; Lucia B Jilaveanu; Annette Molinaro; Mario Sznol
Journal:  Cancer       Date:  2010-11-29       Impact factor: 6.860

4.  Cooperative roles of Fyn and cortactin in cell migration of metastatic murine melanoma.

Authors:  Jinhong Huang; Tamae Asawa; Tsuyoshi Takato; Ryuichi Sakai
Journal:  J Biol Chem       Date:  2003-09-16       Impact factor: 5.157

5.  Elevated expression of protein tyrosine kinase c-Yes, but not c-Src, in human malignant melanoma.

Authors:  F Loganzo; J S Dosik; Y Zhao; M J Vidal; D M Nanus; M Sudol; A P Albino
Journal:  Oncogene       Date:  1993-10       Impact factor: 9.867

6.  Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors.

Authors:  George D Demetri; Patricia Lo Russo; Iain R J MacPherson; Ding Wang; Jeffrey A Morgan; Valerie G Brunton; Prashni Paliwal; Shruti Agrawal; Maurizio Voi; T R Jeffry Evans
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

7.  A requirement for caveolin-1 and associated kinase Fyn in integrin signaling and anchorage-dependent cell growth.

Authors:  K K Wary; A Mariotti; C Zurzolo; F G Giancotti
Journal:  Cell       Date:  1998-09-04       Impact factor: 41.582

8.  Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells.

Authors:  Ralf Buettner; Tania Mesa; Adina Vultur; Frank Lee; Richard Jove
Journal:  Mol Cancer Res       Date:  2008-11       Impact factor: 5.852

9.  Activity of the multikinase inhibitor dasatinib against ovarian cancer cells.

Authors:  G E Konecny; R Glas; J Dering; K Manivong; J Qi; R S Finn; G R Yang; K-L Hong; C Ginther; B Winterhoff; G Gao; J Brugge; D J Slamon
Journal:  Br J Cancer       Date:  2009-10-27       Impact factor: 7.640

10.  C-Raf is associated with disease progression and cell proliferation in a subset of melanomas.

Authors:  Lucia B Jilaveanu; Christopher R Zito; Saadia A Aziz; Patricia J Conrad; John C Schmitz; Mario Sznol; Robert L Camp; David L Rimm; Harriet M Kluger
Journal:  Clin Cancer Res       Date:  2009-09-08       Impact factor: 13.801
View more
  10 in total

Review 1.  Driver mutations in melanoma: lessons learned from bench-to-bedside studies.

Authors:  Janice M Mehnert; Harriet M Kluger
Journal:  Curr Oncol Rep       Date:  2012-10       Impact factor: 5.075

2.  Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032.

Authors:  Elisabetta Vergani; Viviana Vallacchi; Simona Frigerio; Paola Deho; Piera Mondellini; Paola Perego; Giuliana Cassinelli; Cinzia Lanzi; Maria Adele Testi; Licia Rivoltini; Italia Bongarzone; Monica Rodolfo
Journal:  Neoplasia       Date:  2011-12       Impact factor: 5.715

3.  Design, Synthesis, and Evaluation of Dasatinib-Amino Acid and Dasatinib-Fatty Acid Conjugates as Protein Tyrosine Kinase Inhibitors.

Authors:  Rakesh K Tiwari; Alex Brown; Neda Sadeghiani; Amir Nasrolahi Shirazi; Jared Bolton; Amanda Tse; Gennady Verkhivker; Keykavous Parang; Gongqin Sun
Journal:  ChemMedChem       Date:  2016-12-05       Impact factor: 3.466

Review 4.  Advances in the systemic treatment of metastatic melanoma.

Authors:  Melinda Yushak; Harriet M Kluger; Mario Sznol
Journal:  Oncology (Williston Park)       Date:  2013-05       Impact factor: 2.990

5.  A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607).

Authors:  Kevin Kalinsky; Sandra Lee; Krista M Rubin; Donald P Lawrence; Anthony J Iafrarte; Darell R Borger; Kim A Margolin; Mario M Leitao; Ahmad A Tarhini; Henry B Koon; Andrew L Pecora; Anthony J Jaslowski; Gary I Cohen; Timothy M Kuzel; Christopher D Lao; John M Kirkwood
Journal:  Cancer       Date:  2017-03-23       Impact factor: 6.860

6.  SRC family kinase inhibition as a novel strategy to augment melphalan-based regional chemotherapy of advanced extremity melanoma.

Authors:  Yoshihiro Tokuhisa; Michael E Lidsky; Hiroaki Toshimitsu; Ryan S Turley; Georgia M Beasley; Tomio Ueno; Ketan Sharma; Christina K Augustine; Douglas S Tyler
Journal:  Ann Surg Oncol       Date:  2013-11-27       Impact factor: 5.344

7.  Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma.

Authors:  A P Algazi; J S Weber; S C Andrews; P Urbas; P N Munster; R C DeConti; J Hwang; V K Sondak; J L Messina; T McCalmont; A I Daud
Journal:  Br J Cancer       Date:  2011-11-29       Impact factor: 7.640

8.  Predictive biomarkers for dasatinib treatment in melanoma.

Authors:  Alex J Eustace; Susan Kennedy; Anne-Marie Larkin; Thamir Mahgoub; Dimitrios Tryfonopoulos; Lorraine O'Driscoll; Martin Clynes; John Crown; Norma O'Donovan
Journal:  Oncoscience       Date:  2014-03-12

9.  Post-treatment de-phosphorylation of p53 correlates with dasatinib responsiveness in malignant melanoma.

Authors:  Josip Skoko; Jan Rožanc; Emilie M Charles; Leonidas G Alexopoulos; Markus Rehm
Journal:  BMC Cell Biol       Date:  2018-12-27       Impact factor: 4.241

10.  Clinical Significance of PDCD4 in Melanoma by Subcellular Expression and in Tumor-Associated Immune Cells.

Authors:  Thuy T Tran; Chetan K Rane; Christopher R Zito; Sarah A Weiss; Shlomit Jessel; Liliana Lucca; Benjamin Y Lu; Victor O Oria; Adebowale Adeniran; Veronica L Chiang; Sacit Bulent Omay; David A Hafler; Harriet M Kluger; Lucia B Jilaveanu
Journal:  Cancers (Basel)       Date:  2021-03-02       Impact factor: 6.639
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.